Replies to post #135939 on Biotech Values

[mcbio]

Approach sounds interesting and novel but also doesn't look like they have anything even close to entering the clinic. There's no pipeline or much at all to speak of on their Web site. Guess they are mostly at the idea stage at this point.

Actually, just took a quick glance at the prospectus and VSTM has 3 drugs at the pre-clinical stage. Most advanced is VS-507, which apparently inhibits the Wnt/beta-catenin cell signaling pathway. VSTM expects to file an IND for this drug in late 2012. Target sounds like it will be triple-negative breast cancer.

Other two pre-clinical candidates are VS-4718 and VS-5095, both of which apparently inhibit the FAK protein. VSTM expects to file an IND on only one of these drugs in early 2013 and the target doesn't sound like it has been specified yet.